AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
Patrick M McCarthyG Travis CliftonTimothy J VreelandAlexandra M AdamsAnne E O'SheaGeorge E PeoplesPublished in: Expert opinion on investigational drugs (2020)
Future trials utilizing the AE37 vaccine to treat other HER2-expressing malignancies are likely to see similar success, and this will be enhanced by combination immunotherapy. Ii-Key modification of other peptides of interest across oncology and virology could yield impressive results over the longer term.